The combination index (CI < 1) as the definition of synergism and of synergy claims
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The unified theory of the median-effect equation (MEE) of the mass-action law (MAL) indicates that dose and effect are interchangeable, and all dose-effect curves can be transformed into straight-lines by the median-effect plot. Therefore, it allows pharmacodynamics (PD) analysis using small size experimentation for in vitro and in vivo studies. Further, extension of MEE has proven that the Combination Index Equation (CIE) which defines Synergism (CI 1), can be automatically simulated by CompuSyn software within one second after data entries. With adequate experimental accuracy of measurements, the minimum number of only 10 data points are required for quantitative synergy determination in two-drug combinations, even in animals or in clinical trials. Three articles introducing the CI method (in 1984), the review (2006), and the perspectives (2011) have been well recognized and cited 5516, 2382, and 1701 times in 1117, 768 and 530 biomedical journals, respectively (as of 2.10.2018) [Google Scholar Citations- Ting-Chao Chou]. However, the academic societies and governmental regulatory agencies are still lack of guideline on synergy definition, despite over 20 arbitrary, non-quantitative synergy definitions are still applied and reported. As drug combination is the most widely used therapies for the most dreadful diseases such as cancer and AIDS, a call for open forum on scientific credibility and accountability in these matters is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Self-citationDrug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Self-citationChou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Self-citation
Research works printed but not linked: 6
- Chou, 1976, Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands, J. Theor. Biol., 59, 253, 10.1016/0022-5193(76)90169-7 · DOI · Paper page
- Chou, 2011, The mass-action law based algorithms for quantitative econo-green bio-research, Integr. Biol., 3, 548, 10.1039/c0ib00130a · DOI
- Chou, 2014, Frequently asked questions in drug combinations and the mass action law-based answers, Synergy, 1, 3, 10.1016/j.synres.2014.07.003 · DOI
- Fu, 2016, Drug combination in vivo using combination index method: taxotere and T-607 against colon carcinoma HCT-116 xenograft tumor in nude mice, Synergy, 3, 15, 10.1016/j.synres.2016.06.001 · DOI
- Mildvan, 1996, Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clinical Trial Group 068, Antivir. Ther., 1, 77
- Eron, 1995, Treatment with lamivadine, zidovudine or both in HIV- positive patients with 200–500 CD4+ cells per cubic millimeter, N. Engl. J. Med., 333, 1662, 10.1056/NEJM199512213332502 · DOI · Paper page
Cited by
Wooten, D. J., Meyer, C. T., Lubbock, A. L. R., Quaranta, V., & Lopez, C. F. (2021) · Nature Communications · doi:10.1038/s41467-021-24789-z · Cited by 97
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
“CI values below that line are indicative of synergism (CI < 1), and CI values above the line represent antagonism (CI > 1) [31].”
BackgroundSerala, K., Bai, J., & Prince, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70222 · Cited by 6
Metadata
- Authors
- Chou, T.-C.
- Venue
- Synergy
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 7
- Pages
- 49-50
- ISSN
- 2213-7130 (ISSN-L)
- OpenAlex
- W2800379950
- Cited by
- 164
- References
- 3
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.